Sun Pharma Starts Phytopharmaceutical Dengue Drug Trial for COVID-19, an Industrial Info Market Brief

Indian pharma-giant Sun Pharmaceutical Industries Limited announced that it has commenced Phase II clinical trials on AQCH, a phytopharmaceutical experimental drug for treatment of COVID-19. The company has already received approval from the Drugs Controller General of India (DCGI) for conducting the trial.

The drug, which is being developed for treatment of dengue fever, has shown anti-SARS-CoV-2 effects in in-vitro studies conducted in collaboration with International Center for Genetic Engineering and Biotechnology (ICGEB) in Italy and hence is being tested as a potential treatment option for COVID-19.

Listen to Today's News

News Audio Library

Sync News Podcasts

Username:

Password: